Clinical Characteristics and Disease Course of Fibrosing Interstitial Lung Disease Patients in a Real-World Setting
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Population and Data Collection
2.2. Outcome Measures
2.3. Statistical Analyses
3. Results
3.1. Baseline Characteristics
3.2. Disease Course
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Wijsenbeek, M.; Cottin, V. Spectrum of Fibrotic Lung Diseases. New Engl. J. Med. 2020, 383, 958–968. [Google Scholar] [CrossRef]
- Kolb, M.; Vašáková, M. The natural history of progressive fibrosing interstitial lung diseases. Respir. Res. 2019, 20, 57. [Google Scholar] [CrossRef] [Green Version]
- Cottin, V.; Wollin, L.; Fischer, A.; Quaresma, M.; Stowasser, S.; Harari, S. Fibrosing interstitial lung diseases: Knowns and unknowns. Eur. Respir. Rev. 2019, 28, 180100. [Google Scholar] [CrossRef] [PubMed]
- Raghu, G.; Remy-Jardin, M.; Richeldi, L.; Thomson, C.C.; Inoue, Y.; Johkoh, T.; Kreuter, M.; Lynch, D.A.; Maher, T.M.; Martinez, F.J.; et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2022, 205, e18–e47. [Google Scholar] [CrossRef]
- King, T.E., Jr.; Pardo, A.; Selman, M. Idiopathic pulmonary fibrosis. Lancet 2011, 378, 1949–1961. [Google Scholar] [CrossRef] [PubMed]
- Cottin, V.; Hirani, N.A.; Hotchkin, D.L.; Nambiar, A.M.; Ogura, T.; Otaola, M.; Skowasch, D.; Park, J.S.; Poonyagariyagorn, H.K.; Wuyts, W.; et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur. Respir. Rev. 2018, 27, 180076. [Google Scholar] [CrossRef] [Green Version]
- Brown, K.K.; Martinez, F.J.; Walsh, S.L.; Thannickal, V.J.; Prasse, A.; Schlenker-Herceg, R.; Goeldner, R.-G.; Clerisme-Beaty, E.; Tetzlaff, K.; Cottin, V.; et al. The natural history of progressive fibrosing interstitial lung diseases. Eur. Respir. J. 2020, 55, 2000085. [Google Scholar] [CrossRef]
- Lancaster, L.; Bonella, F.; Inoue, Y.; Cottin, V.; Siddall, J.; Small, M.; Langley, J. Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden. Respirology 2021, 27, 66–75. [Google Scholar] [CrossRef] [PubMed]
- Hilberg, O.; Hoffmann-Vold, A.-M.; Smith, V.; Bouros, D.; Kilpeläinen, M.; Guiot, J.; Morais, A.; Clemente, S.; Daniil, Z.; Papakosta, D.; et al. Epidemiology of ILDs and their progressive-fibrosing behaviour in six European countries. ERJ Open Res. 2022, 8, 00597–2021. [Google Scholar] [CrossRef]
- Quanjer, P.H.; Stanojevic, S.; Cole, T.J.; Baur, X.; Hall, G.L.; Culver, B.H.; Enright, P.L.; Hankinson, J.L.; Ip, M.S.M.; Zheng, J.; et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: The global lung function 2012 equations. Eur. Respir. J. 2012, 40, 1324–1343. [Google Scholar] [CrossRef]
- Stanojevic, S.; Graham, B.L.; Cooper, B.G.; Thompson, B.R.; Carter, K.W.; Francis, R.W.; Hall, G.L. Official ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians. Eur. Respir. J. 2017, 50, 1700010. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hall, G.L.; Filipow, N.; Ruppel, G.; Okitika, T.; Thompson, B.; Kirkby, J.; Steenbruggen, I.; Cooper, B.G.; Stanojevic, S. Official ERS technical standard: Global Lung Function Initiative reference values for static lung volumes in individuals of European ancestry. Eur. Respir. J. 2021, 57, 2000289. [Google Scholar] [CrossRef] [PubMed]
- Karlsson, A.; Ellonen, A.; Irjala, H.; Väliaho, V.; Mattila, K.; Nissi, L.; Kytö, E.; Kurki, S.; Ristamäki, R.; Vihinen, P.; et al. Impact of deep learning-determined smoking status on mortality of cancer patients: Never too late to quit. ESMO Open 2021, 6, 100175. [Google Scholar] [CrossRef] [PubMed]
- Olson, A.; Hartmann, N.; Patnaik, P.; Wallace, L.; Schlenker-Herceg, R.; Nasser, M.; Richeldi, L.; Hoffmann-Vold, A.-M.; Cottin, V. Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey. Adv. Ther. 2020, 38, 854–867. [Google Scholar] [CrossRef]
- Olson, A.L.; Patnaik, P.; Hartmann, N.; Bohn, R.L.; Garry, E.M.; Wallace, L. Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis. Adv. Ther. 2021, 38, 4100–4114. [Google Scholar] [CrossRef]
- Alhamad, E.H.; Cal, J.G.; Alrajhi, N.N.; Aharbi, W.M.; AlRikabi, A.C.; AlBoukai, A.A. Clinical characteristics, comorbidities, and outcomes in patients with idiopathic pulmonary fibrosis. Ann. Thorac. Med. 2020, 15, 208–214. [Google Scholar] [CrossRef]
- Poletti, V.; Vancheri, C.; Albera, C.; Harari, S.; Pesci, A.; Metella, R.R.; Campolo, B.; Crespi, G.; Rizzoli, S.; The FIBRONET Study Group. Clinical course of IPF in Italian patients during 12 months of observation: Results from the FIBRONET observational study. Respir. Res. 2021, 22, 66. [Google Scholar] [CrossRef]
- Faverio, P.; Piluso, M.; De Giacomi, F.; Della Zoppa, M.; Cassandro, R.; Harari, S.; Luppi, F.; Pesci, A. Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers. Respiration 2020, 99, 838–845. [Google Scholar] [CrossRef]
- Wong, A.W.; Lee, T.Y.; Johannson, K.A.; Assayag, D.; Morisset, J.; Fell, C.D.; Fisher, J.H.; Shapera, S.; Gershon, A.S.; Cox, G.; et al. A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease. Respir. Res. 2020, 21, 322. [Google Scholar] [CrossRef]
- Flaherty, K.R.; Wells, A.U.; Cottin, V.; Devaraj, A.; Walsh, S.L.; Inoue, Y.; Richeldi, L.; Kolb, M.; Tetzlaff, K.; Stowasser, S.; et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. New Engl. J. Med. 2019, 381, 1718–1727. [Google Scholar] [CrossRef] [Green Version]
- Nasser, M.; Larrieu, S.; Si-Mohamed, S.; Ahmad, K.; Boussel, L.; Brevet, M.; Chalabreysse, L.; Fabre, C.; Marque, S.; Revel, D.; et al. Progressive fibrosing interstitial lung disease: A clinical cohort (the PROGRESS® study). Eur. Respir. J. 2020, 57, 2002718. [Google Scholar] [CrossRef] [PubMed]
- Nasser, M.; Larrieu, S.; Boussel, L.; Si-Mohamed, S.; Bazin, F.; Marque, S.; Massol, J.; Thivolet-Bejui, F.; Chalabreysse, L.; Maucort-Boulch, D.; et al. Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study). Respir. Res. 2021, 22, 162. [Google Scholar] [CrossRef] [PubMed]
- Chen, X.; Guo, J.; Yu, D.; Jie, B.; Zhou, Y. Predictors of Mortality in Progressive Fibrosing Interstitial Lung Diseases. Front. Pharmacol. 2021, 12, 754851. [Google Scholar] [CrossRef] [PubMed]
- Salonen, J.; Purokivi, M.; Bloigu, R.; Kaarteenaho, R. Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases. BMJ Open Respir. Res. 2020, 7, e00563. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Salonen, J.; Vähänikkilä, H.; Purokivi, M.; Kaarteenaho, R. Causes of acute respiratory hospitalizations predict survival in fibrosing interstitial lung diseases. PLoS ONE 2020, 15, e0242860. [Google Scholar] [CrossRef]
- Simpson, T.; Barratt, S.L.; Beirne, P.; Chaudhuri, N.; Crawshaw, A.; Crowley, L.E.; Fletcher, S.; Gibbons, M.A.; Hallchurch, P.; Horgan, L.; et al. The burden of progressive fibrotic interstitial lung disease across the UK. Eur. Respir. J. 2021, 58, 2100221. [Google Scholar] [CrossRef]
- Lassenius, M.I.; Toppila, I.; Pöntynen, N.; Kasslin, L.; Kaunisto, J.; Kilpeläinen, M.; Laitinen, T. Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis. Eur. Clin. Respir. J. 2019, 7, 1702618. [Google Scholar] [CrossRef] [Green Version]
- Raghu, G.; Collard, H.R.; Egan, J.J.; Martinez, F.J.; Behr, J.; Brown, K.K.; Colby, T.V.; Cordier, J.-F.; Flaherty, K.R.; Lasky, J.A.; et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am. J. Respir. Crit. Care Med. 2011, 183, 788–824. [Google Scholar] [CrossRef] [Green Version]
- Cottin, V.; Schmidt, A.; Catella, L.; Porte, F.; Fernandez-Montoya, C.; Le Lay, K.; Bénard, S. Burden of Idiopathic Pulmonary Fibrosis Progression: A 5-Year Longitudinal Follow-Up Study. PLoS ONE 2017, 12, e0166462. [Google Scholar] [CrossRef] [Green Version]
- Suzuki, A.; Kondoh, Y.; Brown, K.K.; Johkoh, T.; Kataoka, K.; Fukuoka, J.; Kimura, T.; Matsuda, T.; Yokoyama, T.; Fukihara, J.; et al. Acute exacerbations of fibrotic interstitial lung diseases. Respirology 2020, 25, 525–534. [Google Scholar] [CrossRef]
Patient Group. | IPF (n = 110) | PPF (n = 142) | F-ILD (n = 194) | F-ILD-U (n = 145) |
---|---|---|---|---|
Gender | ||||
Female | 39 (35.5%) | 49 (34.5%) | 67 (34.5%) | 46 (31.7%) |
Male | 71 (64.5%) | 93 (65.5%) | 127 (65.5%) | 99 (68.3%) |
Age | ||||
Median (min-max), years | 74 (54–92) | 73 (24–89) | 70 (24–90) | 75 (20–96) |
UIP pattern | ||||
103 (93.6%) | 46 (32.4%) | 52 (26.8%) | 51 (35.2%) | |
ILD diagnosis | ||||
IPF | 110 (100.0%) | 0 | 0 | 0 |
Exposure-related ILD | 0 | 60 (42.3%) | 75 (38.7%) | 45 (31.0%) |
HP | 0 | 5 (3.5%) | 3 (1.5%) | 4 (2.8%) |
Mixed CTD | 0 | 2 (1.4%) | 11 (5.7%) | 3 (2.1%) |
NSIP | 0 | 13 (9.2%) | 22 (11.3%) | 14 (9.7%) |
Other diffuse CTD | 0 | 8 (5.6%) | 18 (9.3%) | 9 (6.2%) |
RA-ILD | 0 | 8 (5.6%) | 20 (10.3%) | 8 (5.5%) |
Sarcoidosis | 0 | 8 (5.6%) | 18 (9.3%) | 10 (6.9%) |
SSc-ILD | 0 | 11 (7.7%) | 7 (3.6%) | 3 (2.1%) |
Unclassifiable IIP | 0 | 27 (19.0%) | 20 (10.3%) | 49 (33.8%) |
Time since the first ILD diagnosis | ||||
Median (Q1, Q3), months | 0 (0, 19.0) | 24.5 (0, 87.3) | 35.0 (0, 95.8) | 0 (0, 53.0) |
Smoking status | ||||
No | 31 (28.2%) | 24 (16.9%) | 33 (17.0%) | 39 (26.9%) |
Quit | 25 (22.7%) | 23 (16.2%) | 37 (19.1%) | 22 (15.2%) |
Yes | 18 (16.4%) | 23 (16.2%) | 24 (12.4%) | 22 (15.2%) |
Missing | 36 (32.7%) | 72 (50.7%) | 100 (51.5%) | 62 (42.8%) |
FVC % predicted | ||||
Median (Q1, Q3) | 77.0 (61.7, 87.8) | 80.0 (64.9, 93.3) | 79.1 (63.5, 89.0) | 78.8 (60.0, 88.2) |
Missing | 9 (8.2%) | 0 (0%) | 0 (0%) | 50 (34.5%) |
DLCO % predicted | ||||
Median (Q1, Q3) | 55.5 (45.2, 64.3) | 58.7 (48.5, 71.1) | 63.6 (50.0, 75.4) | 59.9 (50.8, 71.6) |
Missing | 20 (18.2%) | 36 (25.4%) | 28 (14.4%) | 74 (51.0%) |
TLC % predicted | ||||
Median (Q1, Q3) | 74.3 (66.0, 82.9) | 78.3 (64.0, 87.5) | 78.8 (69.3, 87.7) | 78.4 (69.1, 87.7) |
Missing | 20 (18.2%) | 36 (25.4%) | 28 (14.4%) | 75 (51.7%) |
6 min walking test (% from theoretical distance) | ||||
Median (Q1, Q3) | 79.0 (59.3, 103) | 74.0 (53.5, 86.0) | 67.0 (55.5, 100) | 81.5 (60.8, 91.0) |
Missing | 60 (54.5%) | 115 (81.0%) | 162 (83.5%) | 133 (91.7%) |
Lowest SpO2 % | ||||
Median (Q1, Q3) | 88.0 (84.0, 90.8) | 84.5 (76.8, 90.8) | 87.0 (83.0, 91.0) | 88.0 (83.8, 88.3) |
Missing | 60 (54.5%) | 112 (78.9%) | 161 (83.0%) | 133 (91.7%) |
Patient Group. | IPF (n = 110) | PPF (n = 142) | F-ILD (n = 194) | F-ILD-U (n = 145) |
---|---|---|---|---|
Comorbidities | ||||
Any comorbidity | 59 (53.6%) | 80 (56.3%) | 104 (53.6%) | 84 (57.9%) |
Diabetes | 22 (20.0%) | 32 (22.5%) | 32 (16.5%) | 22 (15.2%) |
Obesity | 3 (2.7%) | 4 (2.8%) | 4 (2.1%) | 0 |
Sleep apnea | 17 (15.5%) | 11 (7.7%) | 25 (12.9%) | 11 (7.6%) |
Cardio vascular diseases | 26 (23.6%) | 27 (19.0%) | 26 (13.4%) | 29 (20.0%) |
Renal insufficiency | 3 (2.7%) | 8 (5.6%) | 5 (2.6%) | 9 (6.2%) |
Chronic lower respiratory diseases | 15 (13.6%) | 37 (26.1%) | 50 (25.8%) | 29 (20.0%) |
Malignant diseases | 11 (10.0%) | 18 (12.7%) | 14 (7.2%) | 31 (21.4%) |
Mood and other anxiety disorders | 2 (1.8%) | 0 | 3 (1.5%) | 1 (0.7%) |
Medications | ||||
Use of any medication (as below) | 35 (31.8%) | 59 (41.5%) | 73 (37.6%) | 57 (39.3%) |
Immunosuppressants | 4 (3.6%) | 15 (10.6%) | 20 (10.3%) | 3 (2.1%) |
TNF-alpha inhibitors | 0 | 0 | 0 | 0 |
Selective immunosuppressants | 0 | 5 (3.5%) | 3 (1.5%) | 2 (1.4%) |
IL-6 inhibitors | 0 | 0 | 1 (0.5%) | 0 |
B-cell inhibitor | 0 | 2 (1.4%) | 1 (0.5%) | 1 (0.7%) |
Glucocorticoids | 35 (31.8%) | 56 (39.4%) | 68 (35.1%) | 54 (37.2%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kilpeläinen, M.; Hirvonen, T.; Perkonoja, K.; Hirsjärvi, S. Clinical Characteristics and Disease Course of Fibrosing Interstitial Lung Disease Patients in a Real-World Setting. Medicina 2023, 59, 281. https://doi.org/10.3390/medicina59020281
Kilpeläinen M, Hirvonen T, Perkonoja K, Hirsjärvi S. Clinical Characteristics and Disease Course of Fibrosing Interstitial Lung Disease Patients in a Real-World Setting. Medicina. 2023; 59(2):281. https://doi.org/10.3390/medicina59020281
Chicago/Turabian StyleKilpeläinen, Maritta, Tuuli Hirvonen, Katariina Perkonoja, and Samuli Hirsjärvi. 2023. "Clinical Characteristics and Disease Course of Fibrosing Interstitial Lung Disease Patients in a Real-World Setting" Medicina 59, no. 2: 281. https://doi.org/10.3390/medicina59020281